



Mir Preclinical Services Expands To Meet Its Increased Demand For Service

Distribution Source : PrimeZone MediaDate : Wednesday – December 28, 2005

ANN ARBOR, Michigan, December 28, 2005 (PRIMEZONE) -- MIR Preclinical Services (MIR) has increased its full time staff 27% in the past few weeks to keep pace with the demand for anti-cancer therapeutic testing and imaging services. MIR has also doubled the number of interns who help to maintain the facility and assist in day to day operations.

"We're still a young company, yet we are quickly establishing ourselves as a leader in the preclinical evaluation of anti-cancer therapeutics", stated Dr. William Elliott, Vice President of Pharmacology at MIR. "We are the only preclinical CRO to own and operate state of the art imaging modalities for computed tomography, magnetic resonance imaging, positron emission tomography and biophotonic imaging within our facility. We are not only providing services, but developing new technologies that are helping to find tomorrows cure. The company has more than doubled its work force since its inception little more than 2 years ago and we are planning to move to a larger facility next year to allow for further growth", Dr. Elliott continued.

About MIR Preclinical Services

MIR is a contract research organization specializing in the application of state of the art, multimodality imaging technologies to the preclinical evaluation of novel drug candidates. The company boasts management with over 60 years of major pharma cancer drug discovery experience, and is a leader in the integration of traditional anti-cancer efficacy testing with clinically relevant imaging technologies to provide new insights to drug discovery and development. MIR offers a wide array of tumor models including human tumor xenograft, syngeneic, and transgenic models.

The company is unique in its ability to apply non-invasive in vivo imaging modalities including preclinical MRI, X-ray micro-CT, high resolution preclinical PET, and bioluminescence and fluorescence imaging to visualize biological processes such as signal transduction, apoptosis and angiogenesis, and tumor growth. MIR actively collaborates with leading scientists in academia in developing new drug evaluation technologies with a view to publication of results in peer reviewed journals.

For more information, contact:

Frank Urban

Manager, Business Development

MIR Preclinical Services

924 N. Main St.

Ann Arbor, MI 48104

Phone: 734-821-1063

Fax: 734-821-1066

info@molecularimaging.com

www.molecularimaging.com